´ëÇѺÎÀÎÁ¾¾çÇÐȸ ÇÏ°èÇмú´ëȸ(Á¦15Â÷ ÀþÀºÀÇ»ç¿öÅ©¼¥ & Á¦4Â÷ ºÐ°úÀü¹®ÀÇ¿¬¼ö°ÁÂ) : 2021-09-04±³À°ÀÏÀÚ : 2021-09-04
±³À°Àå¼Ò : ±×·£µåÇöóÀÚ Ã»ÁÖ
±³À°ÁÖÁ¦ :
´ëÇѺÎÀÎÁ¾¾çÇÐȸ ÇÏ°èÇмú´ëȸ(Á¦15Â÷ ÀþÀºÀÇ»ç¿öÅ©¼¥ & Á¦4Â÷ ºÐ°úÀü¹®ÀÇ¿¬¼ö°ÁÂ)ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044
À̸ÞÀÏ :
office@sgo.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
Ãæû³²µµ±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í Àü¹®ÀÇ 3¸¸¿ø, Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø 2¸¸¿ø, ¿¬ÀÚ/ÁÂÀå/¸¸65¼¼ÀÌ»ó ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 10:00~10:15 ERAS in gynecologic oncology ³ëÁØÈ£(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 10:15~10:30 Tumor infiltrating lymphocytes and PD-L1 expression in pre-and post-treatment ovarian cancer during neoadjuvant chemotherapy ÀÌ¿ëÀç(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 10:30~10:45 Incomplete cycles of chemotherapy using weekly gemcitabine affecting prognosis of platinum-resistant ovarian cancer ¼³¾Ö¶õ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 10:45~11:00 Role of ADC (apparent diffusion coefficient) in differential diagnosis of ovary cancer ¼ÛÈñ°æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 11:00~11:15 Diagnosis and treatment of MMR deficient gynecologic cancers ³²¼ÒÇö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 11:15~11:30 Optimal G-CSF usage in chemotherapy induced febrile neutropenia in gynecologic cancer patients ±è³²°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 11:30~11:40 Distillation À̹æÇö(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 11:40~11:55 KSGO guideline 2021-Cervical cancer ¼ÛÀçÀ±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 11:55~12:10 KSGO guideline 2022-Endometrial cancer ¹é¹ÎÇö(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 12:10~12:25 KSGO guideline 2023-Ovarian cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 12:25~12:40 Q&A ()
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 12:40~13:00 Àڱ󻸷ÁõÀÇ ÀÓ»óÀû Áø´Ü°ú Ä¡·á À̸¶¸®¾Æ(¼¿ïÀÇ´ë)
½Ä»ç 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 13:00~14:00 Lunch ()
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 14:00~14:20 Care of surgical menopausal patients including RRSO ¼¼®±³(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 14:20~14:40 Maintenance management of advanced ovarian cancer À̽ÅÈ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 14:40~15:00 Management of bowel complication ÇãÇõ(¿¬¼¼ÀÇ´ë ´ëÀåÇ×¹®¿Ü°ú)
Åä·Ð 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 15:00~15:10 Discussion ÀÌ»êÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
ÈÞ½Ä 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 15:10~15:25 Coffee break ()
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 15:25~15:50 Tumor board-Endometrial cancer ¹èÀ縸À̼ºÁ¾(ÇѾçÀÇ´ë°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-04 ±×·£µåÇöóÀÚ Ã»ÁÖ ±×·£µåº¼·ë 15:50~16:15 Tumor board-Ovarian cancer ÀÌÀ¯¿µ³²ÀºÁö(¼º±Õ°üÀǴ뿬¼¼ÀÇ´ë)